820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797629786146734080 |
|---|---|
| author | Christoph Huber Christian Stocker Kirsten Richter Patrizia Murer Ulisse Salazar Nicole Egli Laetitia Petersen Pia Neubert Alexander Rau Andreas Katopodis |
| author_facet | Christoph Huber Christian Stocker Kirsten Richter Patrizia Murer Ulisse Salazar Nicole Egli Laetitia Petersen Pia Neubert Alexander Rau Andreas Katopodis |
| author_sort | Christoph Huber |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:58:53Z |
| format | Article |
| id | doaj.art-1c1b7dc490854a6cb59a691478325535 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:58:53Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-1c1b7dc490854a6cb59a6914783255352023-11-12T22:45:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0820820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitorsChristoph Huber0Christian Stocker1Kirsten Richter2Patrizia Murer3Ulisse Salazar4Nicole Egli5Laetitia Petersen6Pia Neubert7Alexander Rau8Andreas Katopodis92Department of Cardiovascular Surgery, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, SwitzerlandPaediatric Intensive Care Unit, Queensland Children`s Hospital, South Brisbane, Queensland, Australia1Anaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, SwitzerlandAnaveon AG, Basel, Switzerland |
| spellingShingle | Christoph Huber Christian Stocker Kirsten Richter Patrizia Murer Ulisse Salazar Nicole Egli Laetitia Petersen Pia Neubert Alexander Rau Andreas Katopodis 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors Journal for ImmunoTherapy of Cancer |
| title | 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors |
| title_full | 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors |
| title_fullStr | 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors |
| title_full_unstemmed | 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors |
| title_short | 820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors |
| title_sort | 820 anv600 is a novel pd 1 targeted il 2rβ γ agonist that is combinable with therapeutic pd 1 inhibitors |
| work_keys_str_mv | AT christophhuber 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT christianstocker 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT kirstenrichter 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT patriziamurer 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT ulissesalazar 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT nicoleegli 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT laetitiapetersen 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT pianeubert 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT alexanderrau 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors AT andreaskatopodis 820anv600isanovelpd1targetedil2rbgagonistthatiscombinablewiththerapeuticpd1inhibitors |